No Data
No Data
Akoya Biosciences and NeraCare Forge Exclusive Global License Agreement for Immunoprint Test Development in Melanoma Care
Akoya Biosciences And NeraCare Sign Exclusive Global License Agreement To Develop And Commercialize Immunoprint Test For Early-Stage Melanoma Treatment Decisions, Leveraging Akoya's PhenoImager HT Platform To Address High-Risk Relapse Patients With...
Express News | Akoya Biosciences and Neracare Enter Into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions
Akoya Biosciences and NeraCare Enter Into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions
Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone
Not Many Are Piling Into Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Yet As It Plummets 33%